Retrospective Observational Study on Telemedicine in Sublingual Immunotherapy for Patients with Japanese Cedar Pollinosis and House Dust Mite Allergic Rhinitis

被引:0
|
作者
Inoo, Yumi [1 ,2 ]
Iida, Hiroshi [1 ]
Nakada, Hiroto [3 ]
Tezuka, Katsuhiko [4 ]
Kikuchi, Yasutake [5 ]
Fujimura, Eiichi [6 ]
Nishikawa, Tasuku [7 ]
Yamamoto, Kazuhiro [8 ]
Ida, Yutaro [9 ]
Saigusa, Yusuke [10 ]
Hatano, Takashi [11 ]
Inamori, Masahiko [1 ]
机构
[1] Yokohama City Univ, Sch Med, Dept Med Educ, 3-9 Fukuura,Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan
[2] Medley Inc, Tokyo, Japan
[3] Holon Toriizaka Clin, Tokyo, Japan
[4] Med Corp Sawakou Kai Tezuka Otorhinolaryngol, Atsugi, Kanagawa, Japan
[5] Med Corp Seizin Kai Kikuchi Otorhinolaryngol, Miyazaki, Japan
[6] Med Corp Fujimura Otorhinolaryngol Clin, Nagoya, Hyogo, Japan
[7] Med Corp Nishikawa Nishikawa Otorhinolaryngol, Osaka, Japan
[8] Yamamoto Otorhinolaryngol, Tokyo, Japan
[9] Kamata Ida Otorhinolaryngol, Tokyo, Japan
[10] Yokohama City Univ, Sch Med, Dept Biostat, Yokohama, Kanagawa, Japan
[11] Yokohama City Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Yokohama, Kanagawa, Japan
关键词
telemedicine; patients with JCP allergy; patients with HDM allergic rhinitis; retrospective study; SLIT; EFFICACY; STRATEGIES; ADHERENCE; SAFETY;
D O I
10.1089/tmj.2024.0065
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: In Japan, telemedicine has gradually expanded due to deregulation in response to the COVID-19 pandemic. However, its current status remains unclear, as it is primarily provided by general practitioners. This study aims to examine the use of telemedicine in sublingual immunotherapy (SLIT) for patients with Japanese cedar pollen allergy and/or house dust mite allergic rhinitis.Methods: We conducted a retrospective analysis of medical record data from seven otorhinolaryngology clinics and performed an exploratory evaluation between a group that combined telemedicine and in-person visits during the initial 6 months of SLIT and another group with only in-person visits.Results: Following propensity score matching, 51 and 82 patients were eligible for the telemedicine and in-person groups, respectively, with 33 cases in both groups. Both groups had similar characteristics after matching. No significant difference was found in the withdrawal rate at 6 months from the start of SLIT (6.1% and 9.1% in each group; p = 1.00), side effects, or treatment efficacy between the two groups. The average copayment for patients tended to be significantly higher in the telemedicine group after one, three, and 6 months following SLIT initiation.Discussion: The situation of patients who receive an appropriate combination of telemedicine and in-person visits is not significantly different from patients who receive in-person visits alone. This study may help indicate the actual status of telemedicine in Japan. Further investigation at more facilities is necessary in the future to dispel concerns in the practice setting.
引用
收藏
页码:107 / 118
页数:12
相关论文
共 50 条
  • [21] Steroid sparing effect of 300IR house dust mite sublingual immunotherapy tablet in house dust mite allergic rhinitis patients
    Demoly, P.
    Pfaar, O.
    Gevaert, P.
    Canonica, G. W.
    Casale, T.
    Scurati, S.
    Dolimier, E.
    ALLERGY, 2023, 78 : 217 - 218
  • [22] Comparison of subcutaneous and sublingual immunotherapy in house dust mite-induced allergic rhinitis
    Lee, Sang Min
    ALLERGY ASTHMA & RESPIRATORY DISEASE, 2024, 12 (01): : 1 - 2
  • [23] House dust mite sublingual allergen immunotherapy in Southeast Asian population with allergic rhinitis
    Gan, K. L.
    ALLERGY, 2023, 78
  • [24] Efficacy of sublingual immunotherapy with house dust mite extract in polyallergen-sensitised allergic rhinitis patients
    Choi, Y.
    Rhee, C.
    Lee, C.
    Kim, D.
    ALLERGY, 2011, 66 : 62 - 62
  • [25] House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma
    Richards, Jessika R.
    Stumpf, Janice L.
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (10) : 1019 - 1030
  • [26] Satisfaction of allergic patients treated with house dust mite sublingual immunotherapy
    Aarestrup, Matheus Fonseca
    Aarestrup, Paula Fonseca
    de Andrade, Mariana Senff
    Aarestrup, Beatriz Juliao, V
    Nagato, Akinori Cardozo
    Aarestrup, Fernando Monteiro
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2021, 35
  • [27] Dropouts From Sublingual Immunotherapy and the Transition to Subcutaneous Immunotherapy in House Dust Mite-Sensitized Allergic Rhinitis Patients
    Chen, Huan
    Gong, Guo-qing
    Ding, Mei
    Dong, Xiang
    Sun, Yuan-li
    Wan, Lang
    Gao, Ya-dong
    FRONTIERS IN ALLERGY, 2022, 2
  • [28] The safety trial of sequential sublingual immunotherapy with Japanese cedar droplet and house dust mite tablet
    Matsuoka, T.
    Kuroda, Y.
    Igarashi, S.
    Fukano, C.
    Natsui, K.
    Ohashi-Doi, K.
    Masuyama, K.
    ALLERGY, 2018, 73 : 483 - 483
  • [29] House dust mite sublingual tablets (Actair®): a guide to their use as allergy immunotherapy for house dust mite-induced allergic rhinitis
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2016, 32 (6) : 219 - 225
  • [30] House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis
    Okamoto, Y.
    Fujieda, S.
    Okano, M.
    Yoshida, Y.
    Kakudo, S.
    Masuyama, K.
    ALLERGY, 2017, 72 (03) : 435 - 443